Lyra Therapeutics Q2 2025 net loss $7.4M; cash $29.8M; ENLIGHTEN 2 Phase 3 met primary endpoint

Lyra Therapeutics, Inc.

2025-Q2 EPS reported -$12.00 revenue$366,000

Net loss Q2 2025 $7.4M vs $48.1M YoY due to lower R&D and no impairment charges.
Cash $29.8M at June 30, 2025; $5.0M gross financing extends runway into Q3 2026.
ENLIGHTEN 2 Phase 3 met primary endpoint: 3CS improvement -1.13 (p=0.0078) at week 24; key secondary endpoints also met.
Preparing for Type C meeting with FDA in H2 2025 to align on NDA submission path for LYR-210 in CRS without nasal polyps.
Completed 1-for-50 reverse stock split in May; regained Nasdaq minimum bid compliance.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.